Infinnium^® Paclitaxel Eluting Stent

CE approved

The Infinnium^® Paclitaxel Eluting Stent features a biodegradable polymer that is fully absorbed after 7 months. The proven drug Paclitaxel selectively inhibits smooth muscles cells* and thus favors rapid re-endothelialization.
 
* Limus drugs inhibit both smooth muscle cells
    AND endothelial cells.

Key Features*:

• complete Paclitaxel elution in 48 days
• competitive late lumen loss:
  in-stent 0.38 mm, in-segment 0.18 mm @ 9M
• no residual polymer after 7 months
• low crossing profile: 0.036" for 3.0 mm

>  manufactured by      
Sahajanand Medical Technologies Pvt. Ltd.  ...

  * Lemos et al.: PAINT Trial

Irist^® Simvastatin Eluting Stent

CE approved

The Irist^® DES is the first stent eluting the non-toxic drug simvastatin. Together with its anti-inflammatory P-5 triflusal based polymer the Irist^® DES is designed for maximum DES safety.

Key Features*:

• complete simvastatin elution in 70 days
• MACE 7.1 %, TLR 4.3 % @ 9M
• binary restenosis 4.5 % @ 9M
• in-stent late lumen loss 0.63 mm @ 9M

>  manufactured by Iberhospitex - Cordynamic  ...

  * Serra: IRIST I